Kanjinti

• Kanjinti is a biosimilar to trastuzumab, used to treat HER2-positive breast cancer and certain gastric cancers.
• It works by targeting and blocking the human epidermal growth factor receptor 2 (HER2) protein, which can promote cancer cell growth.
• Administered intravenously, Kanjinti helps inhibit cancer cell proliferation and can be used alone or in combination with chemotherapy.
• Patients should be aware of potential side effects, including cardiac dysfunction and infusion-related reactions, and discuss all concerns with their healthcare provider.

What is Kanjinti?

Kanjinti is a prescription medication used in the treatment of specific cancers. It is a biosimilar to trastuzumab, meaning it is highly similar to an already approved biological medicine (the reference product) and has no clinically meaningful differences in terms of safety, purity, and potency. The active ingredient in Kanjinti is trastuzumab-anns, a monoclonal antibody. The U.S. Food and Drug Administration (FDA) approved Kanjinti, affirming its role as an effective and safe treatment option for eligible patients.

The Kanjinti meaning and origin stems from its development as a biosimilar, providing an alternative to the original trastuzumab product. This class of drugs represents a significant advancement in making complex biological therapies more accessible. The overall information about Kanjinti highlights its importance as a targeted therapy that specifically addresses the underlying molecular drivers of certain cancers, rather than broadly affecting all cells.

How Kanjinti Works and Its Medical Uses

Kanjinti operates as a targeted therapy by specifically binding to the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein found on the surface of some cancer cells, and its overexpression can lead to aggressive tumor growth and proliferation. By attaching to HER2 receptors, Kanjinti helps to block the signals that tell cancer cells to grow and divide, thereby inhibiting tumor progression. This mechanism makes it particularly effective against cancers that are classified as HER2-positive.

The primary medical uses for Kanjinti include the treatment of:

• HER2-positive breast cancer: This includes early-stage breast cancer, often used in combination with chemotherapy, and metastatic breast cancer. Approximately 15-20% of breast cancers are HER2-positive, according to the American Cancer Society, making targeted therapies like Kanjinti crucial.
• HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma: Kanjinti is used in combination with chemotherapy for patients with advanced forms of these stomach cancers.

Kanjinti is typically administered intravenously, either alone or as part of a multi-drug regimen, depending on the specific cancer type, stage, and patient characteristics. Its targeted action helps to improve outcomes for patients with these aggressive forms of cancer.

Important Kanjinti Information for Patients

For patients prescribed Kanjinti, understanding key information about its administration, potential side effects, and necessary precautions is vital. Kanjinti is given as an intravenous (IV) infusion, meaning it is delivered directly into a vein, usually over a period of time in a clinical setting. The frequency and duration of treatment will be determined by the treating oncologist based on the patient’s specific condition and response to therapy.

Like all powerful medications, Kanjinti can cause side effects. Patients should be closely monitored for adverse reactions, especially during and after infusions. Common side effects can include fever, chills, headache, nausea, and diarrhea. More serious, though less common, side effects can occur, such as:

• Cardiac dysfunction: Kanjinti can sometimes lead to heart problems, including a decrease in heart function. Regular monitoring of heart health (e.g., echocardiograms) is often required before and during treatment.
• Infusion-related reactions: These can occur during or shortly after the infusion and may include symptoms like shortness of breath, low blood pressure, and rash.
• Pulmonary toxicity: Lung problems, though rare, can occur.

It is crucial for patients to report any new or worsening symptoms to their healthcare provider immediately. Patients should also inform their doctor about all other medications they are taking, as well as any pre-existing medical conditions, particularly heart disease or lung conditions, to ensure safe and effective treatment with Kanjinti.